Format

Send to

Choose Destination
J Alzheimers Dis. 2019;70(4):1025-1040. doi: 10.3233/JAD-190161.

Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons.

Author information

1
Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
2
Department of Histology and Embriology, Qiqihaer Medical University, China.
3
Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
4
Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA.
5
Department of Psychiatry, Boston University School of Medicine, Boston, MA, USA.

Abstract

 Recent studies demonstrate that peripheral amylin treatment reduces pathology in mouse models of Alzheimer's disease (AD). However, soluble and aggregated amylin are distinct species; while amylin is a physiological neuropeptide, amylin aggregation is a pathological factor for diabetes. We thus hypothesized that because of their similarity in secondary structures, amylin antagonizes amyloid-β peptide (Aβ)-induced AD pathology in neurons with a dose-dependent pattern. To test the hypothesis, we conducted both in vitro and in vivo experiments with different doses of amylin and with its analog, pramlintide. Here we report that a high concentration of either Aβ or amylin alone induced tau phosphorylation (pTau) in primary neurons. Interestingly, with a low concentration, amylin had direct effects to reverse the Aβ-induced pTau, as well as damaged neuronal synapses and neurite disorganization. However, when the concentration was high (10.24 μM), amylin lost the effects against the Aβ-induced cellular AD pathology and, together with Aβ, worsened tauopathy in neurons. In the 5XFAD AD mouse model, daily peripheral amylin treatment with a low dose (200 μg/kg) more effectively reduced amyloid burden, and increased synapse, but with a high dose (800 μg/kg), it more effectively reduced tauopathy. Correspondingly, amylin treatment improved learning and memory in these mice. It demonstrates that amylin has a dose-dependent U-shape effect against AD pathogenesis. Within a physiological range, amylin is a neuroprotective hormone against AD in neurons; but when both Aβ and amylin concentrations are elevated, imbalance of Aβ and amylin may contribute to brain AD pathogenesis.

KEYWORDS:

Alzheimer’s disease; U-shape; amylin; amyloid-β peptide; pramlintide; synapse; tauopathy

PMID:
31306122
DOI:
10.3233/JAD-190161

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center